Impact of Covid-19 GDM clinical care pathway changes, UK data study
Research type
Research Study
Full title
Impact of Covid-19 Clinical Care Pathway Changes on Gestational Diabetes Prevalence and Pregnancy Outcomes, UK data study
IRAS ID
288845
Contact name
Coner Chris
Contact email
Sponsor organisation
NHS Lothian Research & Development Office
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
2 years, 4 months, 2 days
Research summary
Gestational diabetes (GDM), diabetes that develops during pregnancy, is the most common pregnancy complication. GDM can lead to pregnancy complications, including having a large baby but risks are reduced by tight blood glucose (sugar) control.
In the COVID-19 pandemic, pregnant women are considered a vulnerable group. This has led to major changes in the way GDM is screened, diagnosed and managed. Care pathways have been modified to limit face-to-face contact and ‘virtual’ clinics have been rolled out where a woman’s blood glucose levels and pregnancy are reviewed remotely.
These changes were implemented quickly and women and Health care professionals’ had to rapidly adapt. It is now vital to determine the effect that these changes have had on women and their babies across the UK. We plan to capture data from national health records and maternity records to see if the changes have altered the number of women diagnosed with GDM and their pregnancy outcomes.
REC name
South East Scotland REC 01
REC reference
21/SS/0031
Date of REC Opinion
12 Apr 2021
REC opinion
Favourable Opinion